CRHR2 and myalgic encephalomeyelitis/chronic fatigue syndrome: CT38 modulates these same functions in ME/CFS patients, exacerbating them for Cmax >0.25 ng/ml while improving them for Cmax <0.25 ng/ml, respectively, consistent with CRFR2 upregulation and endocytosis (Figure 6).